Off-Label Communication: Industry Opposes Exclusion Of Phase II Data From US FDA’s Guidance

 
• By Brenda Sandburg
  
Off label use
The pharma industry criticized guidance on communication of scientific information about a product's unapproved uses. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Marketing & Advertising

More from Compliance